Regeneron Reports Strong Q1 2026 Earnings with Key Growth Drivers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Should l Buy REGN?
Source: seekingalpha
- Significant Revenue Growth: In Q1 2026, Regeneron reported total revenues of $3.6 billion, reflecting a 19% year-over-year increase, indicating strong market performance in key products, particularly Dupixent and EYLEA HD.
- Strong Dupixent Sales: Global net sales of Dupixent increased by 31% to $4.9 billion in the quarter, showcasing sustained demand and the company's competitive edge in the immunology sector.
- New Product Approval: Regeneron received FDA approval for Otarmeni for genetic hearing loss and committed to offering the product for free, demonstrating the company's dedication to innovative drug development and patient care.
- Share Buyback Program: The board authorized a $3 billion share repurchase program, reflecting confidence in the company's financial position while also creating additional value for shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 709.100
Low
637.00
Averages
808.50
High
1057
Current: 709.100
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Can Eli Lilly Reclaim a $1 Trillion Market Cap?
- Market Leadership: Eli Lilly's leadership in the weight loss market positions it to potentially achieve an 11.7% compound annual growth rate over the next seven years; despite facing intense competition, its robust pipeline of candidates could support significant clinical progress, which may drive a rebound in its stock price.
- Diversification Strategy: Eli Lilly has significantly expanded its drug pipeline through acquisitions, particularly with breakthroughs in Alzheimer's disease, such as the approval of Kisunla, which has positively impacted its stock; further successes in other therapeutic areas could enhance the company's stock performance.
- AI Technology Investment: Eli Lilly has built the most powerful AI supercomputer in the pharmaceutical industry in partnership with Nvidia, and while AI may not transform the business overnight, even modest productivity gains could have a meaningful impact on the company's operations in the coming years.
- Long-Term Growth Potential: Even if Eli Lilly does not meet every growth criterion, its dominance in the weight loss market and extensive drug pipeline suggest strong financial performance ahead, and its impressive dividend growth over the past five years adds to its attractiveness for investors.
See More
Eli Lilly Aims to Reinstate Market Leadership Amid Competitive Landscape
- Market Leadership: Eli Lilly's robust pipeline in weight management positions it to maintain market leadership, although it faces intensifying competition, with a projected need for approximately 11.7% compound annual growth rate over the next seven years to reach a $2 trillion market cap again.
- Clinical Progress Potential: The company's investigational therapies, such as eloralintide, which mimics the action of the amylin hormone to improve tolerability, and bimagrumab, aimed at preserving muscle mass during weight loss, could significantly enhance its market share.
- Diversification Strategy: Eli Lilly has significantly expanded its drug pipeline through acquisitions in recent years, aiming to reduce reliance on its core therapeutic areas, particularly with breakthroughs in Alzheimer's disease that could positively impact its stock price.
- AI Application: By partnering with Nvidia to build the pharmaceutical industry's most powerful AI supercomputer, Eli Lilly aims to accelerate drug development processes; while significant transformations may not be immediate, even modest productivity gains could have a profound impact on the company's operations.
See More
Regeneron Named to Dow Jones Best-in-Class Index for Six Consecutive Years
- Dow Jones Recognition: Regeneron has been named to the Dow Jones Best-in-Class Index for six consecutive years, being one of only eight biotechnology companies globally, which enhances its brand image and market competitiveness in corporate sustainability.
- Free Gene Therapy: The company announced it will provide its new gene therapy for a specific form of genetic hearing loss for free in the United States, demonstrating its commitment to patient access and potentially boosting future market demand through increased public recognition of its social responsibility.
- 2030 Responsibility Goals: Regeneron introduced new science-led responsibility goals for 2030 aimed at driving responsible innovation, reflecting the company's commitment to responsibility in both scientific discovery and operations, which is expected to attract more investor interest in its long-term sustainable development strategy.
- STEM Education Investment: Since 2020, Regeneron has provided over four million STEM experiences for students and committed $300 million from 2017 to 2036 to support science education, aiming to cultivate future scientific leaders and enhance the company's influence in the realm of social responsibility.
See More
Regeneron Secures Accelerated Approval for Gene Therapy Otarmeni
- FDA Accelerated Approval: On April 23, Regeneron announced that the FDA granted accelerated approval for its gene therapy Otarmeni, making it the first gene therapy for OTOF-related hearing loss, marking a significant breakthrough for the company in the rare disease sector.
- Clinical Trial Results: In a clinical trial involving 20 patients, 80% showed hearing improvement, and 42% achieved normal hearing after 48 weeks, which not only enhances patient quality of life but also boosts Regeneron's reputation in the gene therapy market.
- Market Strategy Analysis: Although Otarmeni will be offered for free to U.S. patients, this decision reflects Regeneron's strategic consideration of a small market, with only 20 to 50 newborn diagnoses annually, indicating a thoughtful approach to brand image and market testing.
- Future Development Potential: By acquiring Otarmeni through the purchase of Decibel Therapeutics, Regeneron may use this therapy as a pilot for other gene therapies targeting larger patient populations, further expanding its market opportunities in hearing loss treatment.
See More
Analysis of Cash-Strong Companies
- Quest Resource Performance Decline: Quest Resource (NASDAQ:QRHC) has a free cash flow margin of 3.7%, yet its sales have declined by an average of 6.9% annually over the past two years, indicating a lack of competitiveness that limits its growth potential.
- High Debt Risk: The company has a free cash flow margin of -0.3% over the last five years, and a net debt-to-EBITDA ratio of 7x increases the risk of forced asset sales or dilutive financing, further constraining its ability to self-fund growth.
- Regeneron Growth Challenges: Regeneron (NASDAQ:REGN) boasts a free cash flow margin of 27.6%, but its average annual revenue growth is only 6.7%, reflecting the double-edged sword effect of scale that limits its growth potential compared to smaller competitors.
- UnitedHealth Competitive Edge: UnitedHealth (NYSE:UNH) has a free cash flow margin of 4.4% and has achieved an 11.3% annual revenue growth over the past five years, demonstrating its strong competitive position and profitability in the health insurance market.
See More
Regeneron Reports Strong Q1 Earnings Amid Eylea Sales Decline
- Strong Earnings: Regeneron reported Q1 revenue of $3.6 billion, a 19% year-over-year increase that surpassed analysts' expectations of $3.48 billion, while EPS was $6.75, down 7% year-over-year, but adjusted EPS rose 15% to $9.47, indicating resilience in profitability.
- Eylea Sales Decline: Total sales of Eylea fell 10% to $941 million, yet Eylea HD sales surged 52% to $468 million, suggesting that the company's strategic adjustments to counter competition may be effective.
- New Therapy Approval: The FDA granted approval for Otarmeni as the first gene therapy, which will be offered for free in the U.S., but Regeneron plans to charge traditional prices abroad, a strategy that could help safeguard the profitability of its overall portfolio.
- Ongoing R&D Investment: Regeneron expects to spend $6 billion on R&D in 2026, and despite the pressure from declining Eylea sales, the company maintains a gross margin of 76%, demonstrating its competitiveness and conservative capital management in the high-growth biotech sector.
See More
Can Eli Lilly Reclaim a $1 Trillion Market Cap?
- Market Leadership: Eli Lilly's leadership in the weight loss market positions it to potentially achieve an 11.7% compound annual growth rate over the next seven years; despite facing intense competition, its robust pipeline of candidates could support significant clinical progress, which may drive a rebound in its stock price.
- Diversification Strategy: Eli Lilly has significantly expanded its drug pipeline through acquisitions, particularly with breakthroughs in Alzheimer's disease, such as the approval of Kisunla, which has positively impacted its stock; further successes in other therapeutic areas could enhance the company's stock performance.
- AI Technology Investment: Eli Lilly has built the most powerful AI supercomputer in the pharmaceutical industry in partnership with Nvidia, and while AI may not transform the business overnight, even modest productivity gains could have a meaningful impact on the company's operations in the coming years.
- Long-Term Growth Potential: Even if Eli Lilly does not meet every growth criterion, its dominance in the weight loss market and extensive drug pipeline suggest strong financial performance ahead, and its impressive dividend growth over the past five years adds to its attractiveness for investors.
See More
Eli Lilly Aims to Reinstate Market Leadership Amid Competitive Landscape
- Market Leadership: Eli Lilly's robust pipeline in weight management positions it to maintain market leadership, although it faces intensifying competition, with a projected need for approximately 11.7% compound annual growth rate over the next seven years to reach a $2 trillion market cap again.
- Clinical Progress Potential: The company's investigational therapies, such as eloralintide, which mimics the action of the amylin hormone to improve tolerability, and bimagrumab, aimed at preserving muscle mass during weight loss, could significantly enhance its market share.
- Diversification Strategy: Eli Lilly has significantly expanded its drug pipeline through acquisitions in recent years, aiming to reduce reliance on its core therapeutic areas, particularly with breakthroughs in Alzheimer's disease that could positively impact its stock price.
- AI Application: By partnering with Nvidia to build the pharmaceutical industry's most powerful AI supercomputer, Eli Lilly aims to accelerate drug development processes; while significant transformations may not be immediate, even modest productivity gains could have a profound impact on the company's operations.
See More
Regeneron Named to Dow Jones Best-in-Class Index for Six Consecutive Years
- Dow Jones Recognition: Regeneron has been named to the Dow Jones Best-in-Class Index for six consecutive years, being one of only eight biotechnology companies globally, which enhances its brand image and market competitiveness in corporate sustainability.
- Free Gene Therapy: The company announced it will provide its new gene therapy for a specific form of genetic hearing loss for free in the United States, demonstrating its commitment to patient access and potentially boosting future market demand through increased public recognition of its social responsibility.
- 2030 Responsibility Goals: Regeneron introduced new science-led responsibility goals for 2030 aimed at driving responsible innovation, reflecting the company's commitment to responsibility in both scientific discovery and operations, which is expected to attract more investor interest in its long-term sustainable development strategy.
- STEM Education Investment: Since 2020, Regeneron has provided over four million STEM experiences for students and committed $300 million from 2017 to 2036 to support science education, aiming to cultivate future scientific leaders and enhance the company's influence in the realm of social responsibility.
See More
Regeneron Secures Accelerated Approval for Gene Therapy Otarmeni
- FDA Accelerated Approval: On April 23, Regeneron announced that the FDA granted accelerated approval for its gene therapy Otarmeni, making it the first gene therapy for OTOF-related hearing loss, marking a significant breakthrough for the company in the rare disease sector.
- Clinical Trial Results: In a clinical trial involving 20 patients, 80% showed hearing improvement, and 42% achieved normal hearing after 48 weeks, which not only enhances patient quality of life but also boosts Regeneron's reputation in the gene therapy market.
- Market Strategy Analysis: Although Otarmeni will be offered for free to U.S. patients, this decision reflects Regeneron's strategic consideration of a small market, with only 20 to 50 newborn diagnoses annually, indicating a thoughtful approach to brand image and market testing.
- Future Development Potential: By acquiring Otarmeni through the purchase of Decibel Therapeutics, Regeneron may use this therapy as a pilot for other gene therapies targeting larger patient populations, further expanding its market opportunities in hearing loss treatment.
See More
Analysis of Cash-Strong Companies
- Quest Resource Performance Decline: Quest Resource (NASDAQ:QRHC) has a free cash flow margin of 3.7%, yet its sales have declined by an average of 6.9% annually over the past two years, indicating a lack of competitiveness that limits its growth potential.
- High Debt Risk: The company has a free cash flow margin of -0.3% over the last five years, and a net debt-to-EBITDA ratio of 7x increases the risk of forced asset sales or dilutive financing, further constraining its ability to self-fund growth.
- Regeneron Growth Challenges: Regeneron (NASDAQ:REGN) boasts a free cash flow margin of 27.6%, but its average annual revenue growth is only 6.7%, reflecting the double-edged sword effect of scale that limits its growth potential compared to smaller competitors.
- UnitedHealth Competitive Edge: UnitedHealth (NYSE:UNH) has a free cash flow margin of 4.4% and has achieved an 11.3% annual revenue growth over the past five years, demonstrating its strong competitive position and profitability in the health insurance market.
See More
Regeneron Reports Strong Q1 Earnings Amid Eylea Sales Decline
- Strong Earnings: Regeneron reported Q1 revenue of $3.6 billion, a 19% year-over-year increase that surpassed analysts' expectations of $3.48 billion, while EPS was $6.75, down 7% year-over-year, but adjusted EPS rose 15% to $9.47, indicating resilience in profitability.
- Eylea Sales Decline: Total sales of Eylea fell 10% to $941 million, yet Eylea HD sales surged 52% to $468 million, suggesting that the company's strategic adjustments to counter competition may be effective.
- New Therapy Approval: The FDA granted approval for Otarmeni as the first gene therapy, which will be offered for free in the U.S., but Regeneron plans to charge traditional prices abroad, a strategy that could help safeguard the profitability of its overall portfolio.
- Ongoing R&D Investment: Regeneron expects to spend $6 billion on R&D in 2026, and despite the pressure from declining Eylea sales, the company maintains a gross margin of 76%, demonstrating its competitiveness and conservative capital management in the high-growth biotech sector.
See More
